Sequential screening for diabetes - Evaluation of a campaign in Swiss community pharmacies

Pharmacy World and Science

Volumn 28, Issue 3, 2006, Pages 171-179

  Hersberger, Kurt E ^a   Botomino, Andrea ^a   Mancini, Maxime ^b   Bruppacher, Rudolf ^c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b Swiss College of General Practice/Family Medicine   (Switzerland)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

Blood glucose measurement; Community pharmacy; Diabetes risk score; Diabetes screening; Evaluation; Pharmacy practice; Risk assessment; Screening campaign; Switzerland; Triage

Indexed keywords

GLUCOSE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BEHAVIOR MODIFICATION; BLOOD PRESSURE; BODY MASS; CAPILLARY FLOW; COMMUNITY CARE; DIABETES MELLITUS; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MOTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COUNSELING; PATIENT DECISION MAKING; PHYSICAL ACTIVITY; RISK ASSESSMENT; SCREENING TEST; SWITZERLAND; THEORETICAL MODEL; TRANSTHEORETICAL MODEL;

ADULT; AGED; BLOOD GLUCOSE; COMMUNITY PHARMACY SERVICES; COUNSELING; DIABETES MELLITUS; FEMALE; HUMANS; LIFE STYLE; MALE; MASS SCREENING; MIDDLE AGED; QUESTIONNAIRES; REFERRAL AND CONSULTATION; RISK ASSESSMENT; SWITZERLAND; TRIAGE;

EID: 33750073533     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-006-9034-6     Document Type: Article

References (25)

1. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001;24(11):1936-40.
2. Anonymous. IDF diabetes atlas: international diabetes federation; 1-9-2005, 2005. http://www.eatlas.idf.org/Prevalence/.
3. Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142(8):611-9.
4. American Diabetes Association. The prevention or delay of type 2 diabetes. Diabetes Care 2002;25(4):742-9.
5. Park PJ, Griffin SJ, Sargeant L, Wareham NJ. The performance of a risk score in predicting undiagnosed hyperglycemia. Diabetes Care 2002;25(6):984-8.
6. Rolka DB, Narayan KM, Thompson TJ, Goldman D, Lindenmayer J, Alich K, et al. Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care 2001;24(11):1899-903.
7. Wareham NJ, Griffin SJ. Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. BMJ 2001;322(7292):986-8.
8. Tabaei BP, Herman WH. A multivariate logistic regression equation to screen for diabetes: development and validation. Diabetes Care 2002;25(11):1999-2003.
9. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2004;27(Suppl. 1):S11-S14.
10. U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: recommendations and rationale. Ann Intern Med 2003;138(3):212-4.
11. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26(Suppl. 1):S5-S20.
12. World Health Organisation. Screening for type 2 diabetes - report of a World Health Organization and International Diabetes Federation meeting. World Health Organisation, Geneva, 2003. accessed: 11-08-2004. Report no.: WHO/NMH/MNC/03.1. http://www.who.int/diabetes/publications/en/screening_mnc03. pdf.
13. American Diabetes Association. Screening diabetes. Diabetes Care 2002;25(Suppl. 1):S21-S24.
14. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.
15. Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. Am J Health Promot 1997;12(1):38-48.
16. Gschwend P, Steffen T, Hersberger K, Ackermann-Liebrich U; [Smoking cessation in pharmacies - evaluation of the smoking cessation campaign "Tobacco adieu!" among pharmacists in Basel]. Soz Praventivmed 1999;44(1):14-21.
17. Botomino A, Bruppacher R, Krähenbühl S, Hersberger KE. Change of body weight and lifestyle of persons at risk for type 2 diabetes after screening and counselling in pharmacies. Pharm World Sci (forthcoming in 2007).
18. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 2000;23(Suppl. 1):S20-S23.
19. Herman WH, Smith PJ, Thompson TJ, Engelgau MM, Aubert RE. A new and simple questionnaire to identify people at increased risk for undiagnosed diabetes. Diabetes Care 1995;18(3):382-7.
20. Swiss Federal Statistical Office. Standard Tables of the Swiss Health Survey 2002;2004.
21. Botomino A, Martina B, Ruf D, Bruppacher R, Hersberger KE. White coat effect and white coat hypertension in community pharmacy practice. Blood Press Monit 2005;10(1):13-8.
22. Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K. A Danish diabetes risk score for targeted screening: the inter99 study. Diabetes Care 2004;27(3):727-33.
23. Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003;46(2):182-9.
24. Dallo FJ, Weller SC. Effectiveness of diabetes mellitus screening recommendations. PNAS 2003;100(18):10574-9.
25. Schmidt MI, Duncan BB, Vigo A, Pankow J, Ballantyne CM, Couper D, et al. Detection of undiagnosed diabetes and other hyperglycemia states: the atherosclerosis risk in communities study. Diabetes Care 2003;26(5):1338-43.